Novo Nordisk A/S Sponsored ADR (NVO)
Healthy Returns: First Ozempic generics in Canada will be a test case for Novo Nordisk
New generics in Canada likely mark the start of a decline in international revenue of semaglutide, the active ingredient in Novo's Ozempic and Wegovy.
Novo Nordisk: Mixed Q1 Does Not Break The Thesis, But Also Does Not Strengthen It
Novo Nordisk A/S remains a cautious long, with Q1 2026 adjusted sales and EBIT under pressure but guidance raised on strong Wegovy pill uptake. NVO trades at a historically low 12.5x TTM P/E, reflecting market pessimism despite potential for post-2026 growth and multiple expansion. Competitive risks from Eli Lilly and generics in India and China persist, but higher-dose semaglutide and leading diabetes franchise support the investment case.
Novo Nordisk CEO: Open to deals, we need the broadest pipeline in the world
CNBC's Angelica Peebles speaks with Novo Nordisk CEO Mike Doustdar about the company's quarterly report, the strong launch of the Wegovy pill and what else Novo Nordisk has to come in the pipeline. He says he's always open to doing deals that will strengthen the portfolio and it's part of the company's mindset not to become to complacent or arrogant about Novo's “fantastic” pipeline as it stands.
NVO Q1 Earnings & Sales Top Estimates, 2026 Outlook Raised, Stock Up
Novo Nordisk stock jumps as Q1 earnings and revenues beat estimates, fueled by strong Wegovy and Ozempic demand and a raised 2026 outlook.
Novo Nordisk beats estimates, raises guidance on Wegovy pill surge
Novo Nordisk (NYSE:NVO) reported first-quarter results that far exceeded analyst estimates on Wednesday, driven by surging demand for its oral weight-loss pill and strong international sales. Net sales reached $15.2 billion in the quarter, well above the $11.2 billion analysts had forecast.
Sales of Novo Nordisk's New Weight-Loss Pill Are Off To a Strong Start. The Stock Is Rising
Sales of Novo Nordisk's newest weight-loss drug are off to a strong start.
Novo CEO: 80% of Wegovy weight-loss users new
Novo Nordisk CEO Mike Doustdar spoke with CNBC's Charlotte Reed about strong demand for its weight-loss drugs and a surge in new patients. 🔗Read more: cnb.cx/49ue5z8
Novo Nordisk CEO: Aim to expand U.S. weight-loss market
Mike Doustdar, CEO of Novo Nordisk, discusses the company's GLP-1 pill following the release of the company's Q1 earnings.
Novo Nordisk gains 7% on Q1 beat: is it too late to buy NVO stock?
Novo Nordisk's rebound got another lift on Wednesday after the Danish drugmaker delivered a first-quarter beat and showed that its new Wegovy pill is gaining traction faster than Wall Street expected. The NVO stock jumped about 7% in early trading after the results, extending a strong run that has already pushed it well off its March lows.
Novo Nordisk says the Wegovy pill saw the fastest take-up in weight-loss drug history.
Novo Nordisk on Wednesday narrowly improved its financial guidance for a year where it still sees profit and sales falling after the fastest take-up in weight-loss drug history for its Wegovy pill.
Wegovy sales smash forecasts after pill launch as Novo Nordisk hikes guidance
Novo Nordisk raised its outlook for 2026 after a strong performance from its newly launched Wegovy pill.
Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill
Total prescriptions for the Wegovy pill reached around 1.3 million in the first quarter and have exceeded 2 million since it launched.
